MDT vs. DXCM, ISRG, ABT, JNJ, NVST, SYK, TMO, BSX, BDX, and IDXX
Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Envista (NVST), Stryker (SYK), Thermo Fisher Scientific (TMO), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), and IDEXX Laboratories (IDXX). These companies are all part of the "medical" sector.
Medtronic vs. Its Competitors
Medtronic (NYSE:MDT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
82.1% of Medtronic shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Medtronic had 42 more articles in the media than DexCom. MarketBeat recorded 61 mentions for Medtronic and 19 mentions for DexCom. Medtronic's average media sentiment score of 1.17 beat DexCom's score of 0.96 indicating that Medtronic is being referred to more favorably in the media.
Medtronic has a net margin of 13.63% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Medtronic's return on equity.
Medtronic currently has a consensus price target of $102.41, indicating a potential upside of 7.00%. DexCom has a consensus price target of $97.42, indicating a potential upside of 48.41%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Medtronic.
Medtronic has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
Summary
DexCom beats Medtronic on 11 of the 17 factors compared between the two stocks.
Get Medtronic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medtronic Competitors List
Related Companies and Tools
This page (NYSE:MDT) was last updated on 10/13/2025 by MarketBeat.com Staff
